46 related articles for article (PubMed ID: 10859733)
21. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent.
Subissi A; Monti D; Togni G; Mailland F
Drugs; 2010 Nov; 70(16):2133-52. PubMed ID: 20964457
[TBL] [Abstract][Full Text] [Related]
22. Onychomycosis and diabetes.
Cathcart S; Cantrell W; Elewski Be
J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1119-22. PubMed ID: 19309423
[TBL] [Abstract][Full Text] [Related]
23. New insights into the effect of amorolfine nail lacquer.
Flagothier C; Piérard-Franchimont C; Piérard GE
Mycoses; 2005 Mar; 48(2):91-4. PubMed ID: 15743424
[TBL] [Abstract][Full Text] [Related]
24. Treatment of onychomycosis with oral antifungal agents.
Iorizzo M; Piraccini BM; Rech G; Tosti A
Expert Opin Drug Deliv; 2005 May; 2(3):435-40. PubMed ID: 16296765
[TBL] [Abstract][Full Text] [Related]
25. Ciclopirox (Loprox) gel for superficial fungal infections.
Gupta AK; Bluhm R
Skin Therapy Lett; 2004; 9(7):4-5, 9. PubMed ID: 15334276
[TBL] [Abstract][Full Text] [Related]
26. Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use.
Jue SG; Dawson GW; Brogden RN
Drugs; 1985 Apr; 29(4):330-41. PubMed ID: 3158508
[TBL] [Abstract][Full Text] [Related]
27. Treatment of onychomycosis in the diabetic patient population.
Robbins JM
J Diabetes Complications; 2003; 17(2):98-104. PubMed ID: 12614976
[TBL] [Abstract][Full Text] [Related]
28. The hydroxypyridones: a class of antimycotics of its own.
Korting HC; Grundmann-Kollmann M
Mycoses; 1997 Nov; 40(7-8):243-7. PubMed ID: 9476505
[TBL] [Abstract][Full Text] [Related]
29. Treating onychomycosis.
Rodgers P; Bassler M
Am Fam Physician; 2001 Feb; 63(4):663-72, 677-8. PubMed ID: 11237081
[TBL] [Abstract][Full Text] [Related]
30. Review of antifungal therapy and the severity index for assessing onychomycosis: part I.
Baran R; Hay RJ; Garduno JI
J Dermatolog Treat; 2008; 19(2):72-81. PubMed ID: 18484426
[TBL] [Abstract][Full Text] [Related]
31. [How to improve efficacy of onychomycosis treatment?].
Nowicki R
Wiad Parazytol; 2001; 47(4):823-32. PubMed ID: 16886434
[TBL] [Abstract][Full Text] [Related]
32. Ciclopirox: an overview.
Gupta AK
Int J Dermatol; 2001 May; 40(5):305-10. PubMed ID: 11554991
[No Abstract] [Full Text] [Related]
33. Onychomycosis in children: an overview.
Gupta AK; Skinner AR; Baran R
J Drugs Dermatol; 2003 Jan; 2(1):31-4. PubMed ID: 12852378
[TBL] [Abstract][Full Text] [Related]
34. Ciclopirox olamine: a hydroxypyridone antifungal agent.
Abrams BB; Hänel H; Hoehler T
Clin Dermatol; 1991; 9(4):471-7. PubMed ID: 1822407
[No Abstract] [Full Text] [Related]
35. Efficacy of fluconazole for the treatment of onychomycosis.
Brown SJ
Ann Pharmacother; 2009 Oct; 43(10):1684-91. PubMed ID: 19776299
[TBL] [Abstract][Full Text] [Related]
36. How should fungal nail infection be treated?
Drug Ther Bull; 2008 Jan; 46(1):3-8. PubMed ID: 18171727
[TBL] [Abstract][Full Text] [Related]
37. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.
Gupta AK; Ryder JE; Johnson AM
Br J Dermatol; 2004 Mar; 150(3):537-44. PubMed ID: 15030339
[TBL] [Abstract][Full Text] [Related]
38. [The management of onychomycosis].
Baran R; Richert B
Ann Dermatol Venereol; 2003 Dec; 130(12 Pt 2):1260-71. PubMed ID: 14743114
[TBL] [Abstract][Full Text] [Related]
39. Onychomycosis: review of recurrence rates, poor prognostic factors, and strategies to prevent disease recurrence.
Gupta AK; Lynch LE
Cutis; 2004 Jul; 74(1 Suppl):10-5. PubMed ID: 15287395
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacological characteristics and clinical results of efinaconazole (Clenafin® Topical Solution 10%), a novel anti-onychomycosis drug].
Tatsumi Y
Nihon Yakurigaku Zasshi; 2015 May; 145(5):250-8. PubMed ID: 25958913
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
